0001193125-12-037845.txt : 20120203 0001193125-12-037845.hdr.sgml : 20120203 20120203080128 ACCESSION NUMBER: 0001193125-12-037845 CONFORMED SUBMISSION TYPE: SC TO-T/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20120203 DATE AS OF CHANGE: 20120203 GROUP MEMBERS: INTA ACQUISITION CORP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INHIBITEX, INC. CENTRAL INDEX KEY: 0001274913 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 742708737 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79900 FILM NUMBER: 12567932 BUSINESS ADDRESS: STREET 1: 9005 WESTSIDE PARKWAY CITY: ALPHARETTA STATE: GA ZIP: 30004 BUSINESS PHONE: 678-746-1100 MAIL ADDRESS: STREET 1: 9005 WESTSIDE PARKWAY CITY: ALPHARETTA STATE: GA ZIP: 30004 FORMER COMPANY: FORMER CONFORMED NAME: INHIBITEX INC DATE OF NAME CHANGE: 20031231 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INHIBITEX, INC. CENTRAL INDEX KEY: 0001274913 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 742708737 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79900 FILM NUMBER: 12567933 BUSINESS ADDRESS: STREET 1: 9005 WESTSIDE PARKWAY CITY: ALPHARETTA STATE: GA ZIP: 30004 BUSINESS PHONE: 678-746-1100 MAIL ADDRESS: STREET 1: 9005 WESTSIDE PARKWAY CITY: ALPHARETTA STATE: GA ZIP: 30004 FORMER COMPANY: FORMER CONFORMED NAME: INHIBITEX INC DATE OF NAME CHANGE: 20031231 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 SC TO-T/A 1 d293724dsctota.htm AMENDMENT NO. 3 TO SCHEDULE TO Amendment No. 3 to Schedule TO

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE TO

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

OF THE SECURITIES EXCHANGE ACT OF 1934

Amendment No. 3

 

 

 

INHIBITEX, INC.

(Name of Subject Company (Issuer))

 

 

 

INTA ACQUISITION CORPORATION

(Offeror)

A Wholly Owned Subsidiary of

 

 

 

BRISTOL-MYERS SQUIBB COMPANY

(Offeror)

(Names of Filing Persons (identifying status as offeror, issuer or other person))

 

 

 

COMMON STOCK, PAR VALUE $0.001 PER SHARE

(Title of Class of Securities)

 

 

 

45719T103

(CUSIP Number of Class of Securities)

 

 

 

Sandra Leung, Esq.

General Counsel & Corporate Secretary

P. Joseph Campisi, Jr., Esq.

Vice President & Associate General Counsel

Bristol-Myers Squibb Company

345 Park Avenue

New York, New York 10154

(212) 546-4000

(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)

 

 

Copies to:

 

David Fox, Esq.

Daniel Wolf, Esq.

Kirkland & Ellis LLP

601 Lexington Avenue

New York, NY 10022

(212) 446-4800

 

 

CALCULATION OF FILING FEE

 

 

Transaction Valuation(1)   Amount of Filing Fee(2)
$2,529,313,507.44   $289,859.33

 

 

(1) Calculated solely for purposes of determining the filing fee. The calculation assumes the purchase of 80,398,198 shares of voting common stock, par value $0.001 per share. The transaction value also includes the aggregate offer price for 17,943,006 shares issuable pursuant to outstanding options and warrants with an exercise price less than $26.00 per share, which is calculated by multiplying the number of shares underlying such outstanding options at each exercise price therefor by an amount equal to $26.00 minus such exercise price.
(2) The amount of the filing fee was calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #3 for fiscal year 2012, issued September 29, 2011, by multiplying the transaction value by 0.0001146.

 

x Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

 

Amount Previously Paid: $289,859.33   

Filing Party: Bristol-Myers Squibb Company and Inta

                          Acquisition Corporation

Form of Registration No.: Schedule TO    Date Filed: January 13, 2012

 

¨ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

 

  x Third-party tender offer subject to Rule 14d-1.
  ¨ Issuer tender offer subject to Rule 13e-4.
  ¨ Going-private transaction subject to Rule 13e-3.
  x Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer.  ¨

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

 

  ¨ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
  ¨ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

 

 

 

 

This Amendment No. 3 to the Tender Offer Statement on Schedule TO (the “Schedule TO”) amends and supplements the Schedule TO relating to the tender offer by (i) Inta Acquisition Corporation, a Delaware corporation (“Purchaser”) and a wholly-owned subsidiary of Bristol-Myers Squibb Company, a Delaware corporation (“Parent”) and (ii) Parent, for all of the outstanding common stock, par value $0.001 per share (the “Shares”), of Inhibitex, Inc., a Delaware corporation (the “Company”), at a price of $26.00 per share net to the seller in cash without interest and less applicable withholding taxes, if any, upon the terms and conditions set forth in the offer to purchase dated January 13, 2012 (the “Offer to Purchase”), a copy of which is attached as Exhibit (a)(1)(A), and in the related letter of transmittal (the “Letter of Transmittal”), a copy of which is attached as Exhibit (a)(1)(B), which, together with any amendments or supplements, collectively constitute the “Offer.”

All information set forth in the Offer to Purchase is incorporated by reference herein in response to Items 1 through 9 and Item 11 in this Schedule TO, and is supplemented by the information specifically provided in this Schedule TO.

This Amendment No. 3 is being filed to amend and supplement Items 11 and 12 as reflected below.

Item 11

(a) Agreements, Regulatory Requirements and Legal Proceedings. Item 11(a) of the Schedule TO is hereby amended and supplemented by adding the following paragraph at the end thereof:

“At 11:59 p.m., New York City time, on Thursday, February 2, 2012, the waiting period applicable to the Offer and the Merger under the HSR Act expired. Accordingly, the condition of the Offer relating to the expiration or termination of the HSR Act waiting period has been satisfied. On February 2, 2012, Parent issued a press release announcing the expiration of the HSR Act waiting period, a copy of which is filed as Exhibit (a)(12) hereto.”

Item 12

Item 12 of the Schedule TO is amended and supplemented by adding the following exhibit:

 

Exhibit
No.		    
(a)(12)   Press Release issued by Bristol-Myers Squibb Company, dated February 3, 2012.

 

2

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

INTA ACQUISITION CORPORATION
By  

/s/ Demetrios Kydonieus

Name:   Dr. Demetrios Kydonieus
Title:   President
Date:   February 3, 2012
BRISTOL-MYERS SQUIBB COMPANY
By  

/s/ Demetrios Kydonieus

Name:   Dr. Demetrios Kydonieus
Title:   Vice President, Strategy, Alliances & Transactions
Date:   February 3, 2012

EXHIBIT INDEX

 

Exhibit
No.		    
(a)(1)(A)   Offer to Purchase, dated January 13, 2012.*
(a)(1)(B)   Letter of Transmittal (including Internal Revenue Service Form W-9).*
(a)(1)(C)   Notice of Guaranteed Delivery.*
(a)(1)(D)   Letter from the Information Agent to Brokers, Dealers, Commercial Banks, Trust Companies and Nominees.*
(a)(1)(E)   Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Nominees.*
(a)(1)(F)   Joint Press Release of Inhibitex, Inc. and Bristol-Myers Squibb Company, dated January 7, 2012 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Bristol-Myers Squibb Company with the Securities and Exchange Commission dated January 9, 2012).*
(a)(1)(G)   Summary Advertisement as published in the Wall Street Journal on January 13, 2012.*
(a)(5)   Press Release issued by Bristol-Myers Squibb Company, dated January 13, 2012.*
(a)(6)   Class Action Complaint dated January 11, 2012 (Charles C. Osborne and Hortensia D. Osborne v. Inhibitex, Inc., et al.).*
(a)(7)   Class Action Complaint dated January 12, 2012 (Jeremy Alber v. Inhibitex, Inc. et al.) (incorporated by reference to Exhibit (e)(14) to the Schedule 14D-9 filed by Inhibitex, Inc. with the Securities and Exchange Commission on January 17, 2011).*
(a)(8)   Class Action Complaint dated January 13, 2012 (John P. Hegarty v. Inhibitex, Inc., et al.).*
(a)(9)   Amended Class Action Complaint dated January 19, 2012 (Jeremy Alber v. Inhibitex, Inc., et al.) (incorporated by reference to Exhibit (e)(16) to Amendment No. 2 to the Schedule 14D-9 filed by Inhibitex, Inc. with the Securities and Exchange Commission on January 26, 2011).*
(a)(10)   Amended Class Action Complaint dated January 20, 2012 (Charles C. Osborne, Jr. and Hortensia D. Osborne v. Inhibitex, Inc., et al.) (incorporated by reference to Exhibit (e)(17) to Amendment No. 2 to the Schedule 14D-9 filed by Inhibitex, Inc. with the Securities and Exchange Commission on January 26, 2011).*
(a)(11)   Class Action Complaint dated January 25, 2012 (Ferdinand Alvarez v. Inhibitex, Inc., et al.) (incorporated by reference to Exhibit (e)(18) to Amendment No. 2 to the Schedule 14D-9 filed by Inhibitex, Inc. with the Securities and Exchange Commission on January 26, 2011).*
(a)(12)   Press Release issued by Bristol-Myers Squibb Company, dated February 3, 2012
(d)(1)   Agreement and Plan of Merger, dated as of January 7, 2012, by and among Inhibitex, Inc., Bristol-Myers Squibb Company, and Inta Acquisition Corporation (incorporated by reference to Exhibit 2.1 to the Form 8-K filed by Inhibitex, Inc. with the Securities and Exchange Commission on January 10, 2012).*
(d)(2)   Tender and Support Agreement, by and among Inhibitex, Inc., Bristol-Myers Squibb Company, Inta Acquisition Corporation and certain stockholders, dated January 7, 2012 (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Inhibitex, Inc. with the Securities and Exchange Commission on January 10, 2012).*

 

* Previously filed.

 

4

EX-99.(A)(12) 2 d293724dex99a12.htm PRESS RELEASE Press Release

Exhibit (a)(12)

 

LOGO

Bristol-Myers Squibb Announces Expiration of the

Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc.

(NEW YORK, February 3, 2012) – Bristol-Myers Squibb Company (NYSE: BMY) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (HSR) for its tender offer for Inhibitex, Inc. (NASDAQ: INHX) has expired.

Bristol-Myers Squibb initiated on January 13, 2012, through its wholly-owned subsidiary Inta Acquisition Corporation, a cash tender offer to purchase all outstanding shares of common stock of Inhibitex for $26.00 per share.

The expiration of the HSR waiting period satisfies one of the conditions to the tender offer, which will expire at 12:00 midnight (New York City time) on Friday, February 10, 2012, unless extended in accordance with the merger agreement and the applicable rules and regulations of the SEC. The tender offer is conditioned upon, among other things, there being validly tendered in accordance with the terms of the tender offer and not validly withdrawn prior to the expiration of the tender offer, a number of shares which, together with any shares then owned by Bristol-Myers Squibb and Inta Acquisition Corporation, represent a majority of the issued and outstanding shares plus all shares which Inhibitex, Inc. may be required to issue as of such date to holders of stock options or warrants.

MacKenzie Partners, Inc. is acting as information agent for Bristol-Myers Squibb. CitiGroup Global Markets Inc. is serving as financial advisor to Bristol-Myers Squibb in connection with the transactions and as the dealer-manager for the tender offer. Kirkland & Ellis LLP is acting as legal counsel to Bristol-Myers Squibb. Credit Suisse Securities (USA) is serving as financial advisor to Inhibitex in connection with the transactions and Inhibitex is represented by Dechert LLP.

Forward Looking Statements

This press release contains “forward-looking statements” relating to the acquisition of Inhibitex by Bristol-Myers Squibb and the discovery, development and commercialization of certain biological compounds. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the acquisition will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the acquisition will be realized. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2010, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Additional Information

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Inhibitex. Bristol-Myers Squibb Company and Inta Acquisition Corporation have filed a tender offer statement with the SEC, and have mailed an offer to purchase, forms of letter or transmittal and related documents to Inhibitex shareholders. Inhibitex has filed with the SEC, and has mailed to Inhibitex shareholders a solicitation/recommendation statement on Schedule 14D-9. These documents contain important information about the tender offer and stockholders of Inhibitex are urged to read them carefully when they become available.

These documents will be available at no charge on the SEC’s website at www.sec.gov. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge at www.bms.com or by directing a request to Bristol-Myers Squibb, Office of the Corporate Secretary, 345 Park Avenue, New York, New York 10154-0037. A copy of the tender offer statement and the solicitation/recommendation statement will be made available to all shareholders of Inhibitex free of charge at www.inhibitex.com or by contacting Inhibitex, Inc. at 9005 Westside Parkway, Alpharetta, Georgia 30009, Telephone Number (678) 746-1100.

In addition to the offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, Bristol-Myers Squibb and Inhibitex file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Bristol-Myers Squibb or Inhibitex at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Bristol-Myers Squibb’s and Inhibitex’s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

Contacts

Bristol-Myers Squibb

Media: Sonia Choi, 609-252-5132, sonia.choi@bms.com; Jennifer Fron Mauer, 609-252-6579, jennifer.mauer@bms.com

Investors: Teri Loxam, 609-252-3368, teri.loxam@bms.com; Timothy Power, 609-252-7509, timothy.power@bms.com

Inhibitex

Investors: The Trout Group, Lee M. Stern, CFA, 646-378-2922, lstern@troutgroup.com

GRAPHIC 3 g293724img001.jpg GRAPHIC begin 644 g293724img001.jpg M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D M``#_X0,I:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@ M8F5G:6X](N^[OR(@:60](EG)E4WI.5&-Z:V,Y9"(_/B`\ M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)! M9&]B92!835`@0V]R92`U+C`M8S`V,"`V,2XQ,S0W-S&UL;G,Z>&UP34T](FAT='`Z+R]N&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N M861O8F4N8V]M+WAA<"\Q+C`O&UP34TZ M26YS=&%N8V5)1#TB>&UP+FEI9#HS1$)!1$9!.31%,#4Q,44Q.3-$,$0S,#A" M-$9!-$8R-B(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HS1$)!1$9!031% M,#4Q,44Q.3-$,$0S,#A"-$9!-$8R-B(^(#QX;7!-33I$97)I=F5D1G)O;2!S M=%)E9CII;G-T86YC94E$/2)X;7`N:6ED.C-$0D%$1D$W-$4P-3$Q13$Y,T0P M1#,P.$(T1D$T1C(V(B!S=%)E9CID;V-U;65N=$E$/2)X;7`N9&ED.C-$0D%$ M1D$X-$4P-3$Q13$Y,T0P1#,P.$(T1D$T1C(V(B\^(#PO#IX;7!M971A/B`\/WAP86-K970@96YD/2)R M(C\^_^X`#D%D;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$! M`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`(0#:`P$1``(1`0,1`?_$`+@```$# M!0$!```````````````'"`D"`P0%!@H!`0`!!0$!`0```````````````P0% M!@%"4B,5L=%#)!;Q8H*2,W*BTE,T1*0U1?_: M``P#`0`"$0,1`#\`]XENL,53X"9M,TO^780<8X>.54DU'#LP-D#K'0:-T2*J MKNU2EV23(0YCG,``41TC!M++O=63A%U#G_XA[<,KK<'6>V%CEUAN7BGL(Q%A M5,X=J[9E9Q$6*69TN+GB6MW5,<59C449V595R'B/:N._O&7LB-*19IS'>5\E"C5"J-)VPW^AXPK%:K-@; M$'E5@@5,>Q-GL%BD')TVY6:"0M4SJE5,]3(('U%;9M%D[HG:/,<`B:B:&I-0 M&@4JM5TYD`VB[WR[9M9@9\0"9-`R*?E2O+"A=1\P95N`RU(SHSC$K@T/$JU6 MR1K5S"FN4`TJ-.EYAS*0KE(8YE:FZ]D:+O46Q@`K=\"9``69C#&]R[!:MC=* MP]&@@@+12@XT%#7F`.)(>]E;[9`(WOMY`YK@T* MH((.1!%#S!Q&;]N^W[6UDMRX>8P@@'55#04:[&LQQF/$^86:LGC#(]%R*Q8J M`B[?4BUQ5F;M%"FV!-PO#*K(%$!^@1#?3Z[V.;;K;^-?$8[31I0E:XC$O)<;;O#]F[+6:^>)3G9R(A5)N291$+^K2;"/-+2S]=-FPB(W\Z=-=_(/W2I$TD4^2 MBBAP*4!,(:Y"^\W.$7L#'?+1=;D0A&J2<@13PQQUW;;9,VPG(USO#`"HJ_I" M(J^\XVSQVSCV+N2>N4H]FS:.'+MXNND@@S;((G57=+.7.S=!)NF03F.I]P@! MN;P`Z3MI+CX-<'!. MDFJ+7ZL'\A:WT#IX#JDB:2/BS"D9I]^,2SY`H],*Q5N-OK-12?APC2V&>AX0 M9%<@??:L49-1%=TJ<1X\4@,<1'8-A$-(PVFXF^%E`P_(99M^K]7O7QPE)?6( MLQ>S$?/:5_,JIS^&OLQU#9T1P@DX+[9T%CMU2JIK%7;K)*AN@X14#<#AX`2[ M>!`0'?\!O\`1I?2WE]N%?F;#Z:O[8.:8^/<]?'X#?3^[74:*I@,ME(/ M+9\;J#XLS08NDX;<=]_/U"'[]-KB*.;J=F/;AS#"Z!B<,4K`()J%(0!Y$,'D M=P'9/V9!^TZCC_NFAH*YW46?UF7R%5(Z9;IH%$ZI5XM],C(-BD`H[[$$WU!I[! MLUZ)A>W#'!"JE![T7[L5Z?N[LJWN#V]N-715V[ILX(1=J];.TC"DY:G3-N4"B('((#Z#Y]W7E2R%[W+ MH:4H1EPI]?+$HT;?M;6#MQJVUR]H>5=\+J:OW=1RX!"."''4;_1ZCZ_5J-\V M)W&GOQ)`2-%*_5B@_@IAXAX*8?)^(>@CY,&_$/M^C08F.:=.9'CCGFR--10> MS'*S]LK=38FD[)-Q4''?J+9B1],R!(AN=V[4(F@U1<+B`.5U5#`4B8?C-X^W M2]GM3R/(C!KS<3/Q(NU6H2<-(L))@JZ9 MK>TZ9G<-3J_XIJ8A@$I1W*.V_P!6NRPNV=ODS`@^-$7V$_2F$[*Z@WN#SXBL M?O\`O#4KCI/<2_J?1_6-_D]--OY!GV+[OJPY_CX_HO\`?$>N8^R5(DB MY&.FYG$\@RM=NK;FQ0E4BG5L1(TEZ-&6"V6%-:OQ\/&M9$TU(E226DT'*#`R M:9S_`'#7[9>U;D;+_(J?AHC2XY5Z0Y<^*$)U98SCN#NRU&[_`,?^50,R.)&9 M84RY^&$%S+8DJUC[]3GK9CA[9*3;K/EBDY)QE9VSG^7)";M4A:Y.M62ENCNY MLU?3;.1;1[I%5^V>+LF0J"S*8HEE.W[.ZOKEUDKM#QH(<,PB`A4"U0A0:DFH MQ`[W,%[O3;-P6,O-%(S//0/ZTPYNSWA>HH66WV"Q8K MDY5Q=?\`Z]7I'%U^0F)W'\_%URN4UQ$24!+)D=VRMW&)CACY229)HI-4))90 M&:)2%=!49-NGO2;&-LK`]GEC6Q`05#4)(32O$@GC4*-)W##LTX#\9`,99#J^7-WM?ML(VF8Z0:CN0$7@`LOQ,8//MO$C%- M_K%_?JC[OM$^RRNMISU,(7+(A5S/,"@"" MQE@#@"9^7$=^]*WP7W9^[VH!==264S(@I!UNB0(5#:O-%(`*J4J/GKU/;<6G MJ)LEQ.Y-N;NELZ4H#^V)@79*[X`?AZN5<<9ANVXJRM\LLEFOKB>-QAC+$>`; M)7>P#%>O.,;V?*\N1%R[@9!GAEU`060;!#5IO(-#?JHM19@+$J12GV)S:3[= M-#VA_!W3?.WB29C&-!0-U.:`TO/1FO6XCJ<&`@Z3AIVCOG:MQZT;AN5N=.WP M-N22DM2V4#4!I#N(II*@:G"IQ(%1/D_ZDYP?.JQ1IC*DVSE8O(R4E:HK%.5F ML%#HT.*>K6A.7L+.NHN*K)@V;*&9@4R:ZIRA[8@8P"&;6/IIO?;]X#.UKIIY MVZ!J;F7(`")'`UXNT^Q4QHMGZK=G=Q;EN^W[:]QN+"TN'$Z9O\(AH(#XF`*H MHI'-<)OUC[7=0NO?5O`<-BJUYPRM4,KWW(E5PPRG(FW7[,5]FHNS6:2N'MQS MIHE/JP-==D7]KW@2.1$$PVW,(ZD-_P"T[]M^^*=K&!K=11ZM`.H"I+:JTDT` M`3WK]O>H%FZS#FDN)H*$%?8&'V#F0<([VX^21T[ENF,AAA/-]5KUG[>-:+F: MM+X:GPNSYC332,?:,7.H1T@26:VA20]HRL2U`[J5:F%%(>9RAJS[-Z87=UVW MN5]*Z)SHMO?*S2X.*:)'!Q&MH1SF=!Z@2UR95JVZ^L%G;=T;?8`/$4E]%&]0 M10R-:0/VB5`)5"#EA]ET^0;"%9N#Q7BRW79_B)A,1 MJE@;DR@$8W,TK4PY8-#G)'"&#=[\B8<["OOBQSY MBV2@;M"S?>3$4;6+FR2[@VZ[!0[7*&!74-9&2UX<$15!%5!YTYX^@=SVZ3<=D>]R&302%1,C0U`R./* MQTINTETF[EW"RO56T?U;[D]K,^X+.Q38IPE>QEFC'62K0VQO)K**D$C5I>*P M[6:G$=@(`\!\,-?1O<6PVG=?:=Q):$-W2"S\U*GI1ZBH"ZM#B`T#K:S4C<_E MSM#N*_V?NB."Y*VYN4=\(0!R$T:3E]BI7&'V_L#[L-\C717,4\5.QX*>]FK+ M@_$M4E(Y":@;95L1*1[N_P"3%H5RFLU?EO>3O=8,U5$Q3,A7F)C%$##N\[-V M?:X/3F[VI_\`]W#:ND>\N<&ASXG:0=+RUI:(P79(TM=5:1/>?<>XN]1V;G"4 MV*L!HT'X07&J*H M&.*EODEP&@VK+>LQ^9LAV>ST`EM;CL#.JBHVN>=,Z&B5P6WJOM]X\,9KYE`ZE>/[8^OQ''#[X:S1^2<>Q=MJ, M@7].O%4:6&I23IJ=#\Q'VN#5?U]8[9\9)PU609OR'52^ZH``(;!N)0I;=O?M MN\023=4,5RPO;2H8\%P52:C(@>S%PO+L]P]MWMG9'3=W-G+'$[,!\D;FM)4- M!()OH7N>&ZWW9H]][?G6R;&6R0*Y M'(3U!0%<&NZFNTD!O2=2C'S%L6X]C]N;X>TN_P!H_F=;6EY$R@DD#_H!S`"1 MF'I^HH1B=*X]F,(].V>&^MPKY.RID1.BQ;6H8WQS59W*&5Y2BU**<0[6[V!E M$%0(WBA)$`V7?+"DF+]1,1$"CN&+;+V9N&ZFXN@Z-MM&"KI'B,!7(BEW`D"O M%`*Y?0.Y]Z=M=F6T%I9ASVW"-C`$KB%"@C4QY.7$CIH4&$YA_E=ZGR%-EKRI M)9$A:]&YI@NO39:5Q]:6,O+98D&-?<.8)*-FFYVS@`QA_XA2I1>M:T1`0J@D("8NU]4;&Y.DK]OO3]L#.G#@>:. M3ENX6$8W/,AUE?S\HGE)EC"4RQ(12%2LZD=$TN,*0JSM::3:?E'3Y5NINFT9 M*<''C3[<62/NVTN#Y*$2."5U#/FK!]*` MX@0[,QG6RP_&53[#@*P9%R52J]WVIRD'?-P"*7GT&\FPK MS\YA9-4`3(4$U"E`!-YUN/;^PW-WW):P[@V("3MZ.:,1EYZ'2M#=9\LPW=B^(VD'<(@+FG5UL1^IH_,P@*'<4J,L:/<]T1RV4UE'J#Y.SWSA0!1 MS2U/A*&N005IB./XK^V>*NO72'KY5LB15YKM6M%_OD&WR@E09M7$L1-6W,%J M8UB+G[M'I*L&#^>D7:#%MR#@"JA`.)2^1M???:[KR_=);F-1$NC4CRCC5"?A MJBY+2F>*OZ9]WNM[9L$VHL)3()ES##6F7!%KCT#9^%<^'_`"_3EB./+G7%J7.HY`2GWP<.*9M M!V+O&[@V0614.#34:5`1%"QD%.*\*YH#FF_=EV\V\?.CX"X%*YJ3^L'[,(-E M2F5];'#^;A\=/,3N#3LEBRO1M?N]AN66+CD&&L,Y6WL95U/UU[5Z]&Q3^/=N M2OG)I%S)$`J!@9B8-Y7M[N"\M;ASGNI6*+;O(^;"):OG)(I"1(NC,NW:II%4X(-P$)B[WZ*>%YM6]3AK.@-#B7 M?GJT!SJ+551*XH6V=LRV.\LNI3T,)`54"%4HXD>P"BX7VT8SB9N#M4?'8EC< M;2E;FVU",XB+].WJT6C(4RS@%X6!H:C.9!M$5Q-2QI++OI5$JT603K&8H>T9 MP6M17TEK*+P2.E+/W&JT-0-.II/3F4040U.E,K]OU@-Y$5J``S6&NS6M"!4< MUI7QQ(SB'';7$^.:?0F4K(6(*]"M6BTY*O/U.4F'ASBY>R;AVJ)3*'E7:AU. M0\2AL'U;ZSGN'>[G>]R=/,!J>X'A[!DUO#CC4NU^W[78=N^6@-`/$4KS<[PI MQQ"?\H-[94GOY\;-XLL#=6./L2W6XV*[Y):4Z??4:#87-NP@HIK-V^)25:M3 M(NHH556ZA3E%$=Q`0-MK=O3O;[6;M+IE_N-OW;97,3%@BN8WN/1DU^HYA33D/#''98M=3[>?)7U.S5UF1E);&_ M6:G7BS9\[&,82J\;T1&<-7R_P`\/73=HJ`H(FXH`]$2[>=F?:,E MKVSZ:[EM,[A\Q=;S*6Q<0YULR,N!)<#72O50-49U7[Z9>=S^H=EN,`)A9L4; M22:#_,RO1#I('7P"5YX6;XC[9!0/2/-+R57D(!Y7M M-SZ+=6,/Y\M&43,TM>I(PGC4T-4)Y MBF'0]-,[8VZC9$[SQO8^4EZ]_Z=@L',>^&UMX2`3TR#2`UW`$',5( MH4.+KV)>[A:;7W0VX:6FXENGM4"HW M4%MD/Y77O:Z"H#VNV26L&.\"S,JT:L9.U0K.O#(UV,(9`9/W7P`B@F.Y]P*8 M`O\`)N^VC?=]NHI`]>W;J)0O_44*TH*$(%H`%1>`S*]V/(R.:@)0&H15+.9IU*HY MX^B-VV*66S,C9'`"JCW\-7OR3$=_7O!.)N_74WMMU^F)BQU].8[?YPR!6K*6 MIRT+8:>VLF4Y&T8QO,&YM<*U8N%+!$-5%"':[F%-R8H"01*<+*>ZI]KWN#>( M.IT36*`E2QY?0%IJ"A4@A%''%5V'M,7>WW.VST9,'M/L>T--0]X=P[8[MWN]3Y^[ANR`-57OBDD<*-T@:GA%I7@!6E][]M MW=GZA=J;?;!=MM'V#2>D49,448NJ'8\4.F!\D71H5,P.5U[OA5V\;%X"4ZBY0V`!VTRV*_L=\ M]-2W=D%YM-T96+Q8Z,!C%:&CK>T9DG4QJ@KB:[QL[C;/5"%^T`EE_91PR#@" M9WEQZB5TAK30"A(!%52BWUN5Z\]Z^VD+E?*]JZO8P[)L<(RF,2 M'EB_?G>`:?G[XEX'!E!L]`PGC;+F7)5DUE\<72,5;5FPU4]6@,H/DG\.,XC7 M\D7%J9-M,6`R+UR[6!4X`UW,,;VXZ&'M[?6W!'FS[=,P)JH3$_I-2!IU>`(( M*DKB=WR"\F[GV.1C3Y4.XV[C5M=,P4C(U`',\.&+_P`BTUC&!S_EC,F&LL9# MZW=Y<'5RILHHJ$#+RU%[6085B*L\!37-89\8Z]%=+R246"IQW9J-P`Y13Y&( MY[,D-OVLS;+MD-QM$K)%-=<+@VB@T>%`0MZV.)JC6K&^H-E=7W>7SUOJCF9( MSBU'#60[1CH8S+9L&1=MF\6D`6!VE^2H[24D MJ$7BDL:-%6=3(P!$"F$@EVV,(#K)X]NL;G?FVYD2":X##)4HU[@"Y%J&BIKP MSQNEGN5]8[(RY#%E@BU!J@+H"HJ%%3-"F(..W?=+IUWAZ.3\'8Z9!PGO;N+MWO3TSW*SEMB-^DWAS MV1ZWH)!'5VL-C80A+0'%,Z)I(TG5$UOZ/]N:;D'N^\D*XCD_H#A''T#DF0B9 MF9@(C(U+$`+E)TJ$,-Z:VC>V^\;67NBV,9_P!-,@B.LNZA M)%I;^WJ0@-V4^)(SIC=Z(RR9+T.]P5,GK&G:75D-$PLO.5IJ+EW$P[YFUS;/IO+=_,A94U$36.ZM7EY:CFG`#+%OVG==YD]2NEJV?^F/)56#_W M+2B(7>%/KQ'>]MJ+/XHG513KF0W$TU^0P+HM$HXWNKN0C:8TR2E>VT_)-DJW MRBH]6I1JJK[.O=O`_<=W+,_\M6F`-!_-^G)5^^1[).2ZOVS[[=7LSX&-8;YB3J1A;-5 MWRYE"K5:2?5TSB\4]JWK>/H)5W7#.[K9K"U:+*#%MN2H'3*F'\0VP4O:H+6R M[.FVVX>&W\N_=,:N!41:"X:20C7/&IS%(:`4/2!-;HW<-R[ML^X(`=-KVU'U M=)"MD<].I,VDIJ:0NXN,/F7XCX[H'2369;M5?LM-(&.Q>XJ=I:6JM-4NT M#/++N[V'\S!((LZY`8_;*OW$HL8B*I$?:$VX")7&YVL4.^LW-SVMVZ.WTEQ) M%3J&E,^(8'16;*)O8> M012<(F(JF<%$@V,`^=5.'=([;=6VZ!S04XU'++CS7%JO-N-QM3G$D3:5R&:> MU*T22,`HXKD>E'?",Z(!4HA'IMKIH@YQ1GG[=4UL\5T-4=6^_P"],:-:VTELS2\J/8!]YQ2JW34*;W2<@XB&_(0\ M;?440TDZXNH'AS?@U>']EPG<[?:7@+96JYP3,\?81BT5))(R8II@7[A2<]S# ML3P@! M-MP$-^1A^CZM]+^9<<37W83^2M&!`VGM/]\6#-TS;EX;[>?Q#Y_=O].N&6Z& M7+PQQ^VV,C:M^UW]\6R-4-C%]OCR5`1W$P[F`?.WD=O7[->3)<3$.?\`X9\* MI]/'"3-NL[(.C:*39U=^;WG[L7SH(@F!./X#`O\` M4$X<<1O_R\G6B<'5537+@@]F/+ MV6]S:BT?6[B:@S%6A/9GXG#1JCU]LB/;"Z]C\@7F/LC%+'T3BO!M&90PM2XX MA74D>QY&GWTDL/NR%JO\BWCRNA+L4K.-3*&X;E"7_P!5P;QM,NR;8HB:2Z3, MJY-(^)C=(72&@.("`>.*YM7:8VWEY!R*G2BJN:8>$)2\ M>9QW``\#MMZ!X\!YU!VT=U&D1=T>P8M-Q\HYAG<.'^]]/LQ8/[0@4_'<`,`; M[F#8?([_`&[;:5N))HBV):2$-.7>RPA!'9S,=@_5L'UZ5C=-&?)<5`&=,*MM;*[2ZWF/Z8N+'`J2A@/L M":9Q'[N^P%*(_2`[[;:973?)(NI7)`TZGE,FBIRKER"X5$@D8Z&UK.A#/^TA M3.F?.G/&`EP.4JB9^7,@JF)L(1,;D8`X^GI]FN7#'[E$+F.X3:W-%/+!5 MO&I1X4>"C#.-@LO\I+"NY..L]>;CQHK,QDJ>&,8Q#J-G2;8J:#@Y53(^]R<( MF6$@@G[I"F2,*0J"'(`.41#T$/77O:YMKDE:-LE)A8]ID`:X$@$*`9`4*9$` MIR..R&_GC?\`R<(:][?+8=;3\0*48GCG]>(_ND?5+)W6*7["/[Y?:'=4,ZYJ ML.;A+4JS+U\T!;+@]*>RQ0.7,T[!Y!E3:IE:D,7D5P8PF#81*-V[B[H9O$<3 MHVD,A9Y(!*T"H%+=4S1N.KJ?^R3J1&_\O/+CC1;0[;%= MRO8U)F-[#:XVBRO&>611SM>;LRH_4.?X8H%NFF4#!X`B8%WW,/W2AX+MZ^?K]=`N MKAS]"*X]7`4Y984BM+&QB,A%&Q^6:NR"4S/+\<8R6Q53<2[G$WNH_MTYD?,]@0(,N&?''N.+;G7S&1M1QM0\5=S\?IX8R/>'_G\?]WZO37C MRI?U?E7(8;ZF_P#S/+]WT_VXVFDL2F#1@P:,@P:,@P:,@P:, M@P:,@P:,@P:,@P:,@P:,@P:,@P:,@P:,@P:, &@Q__9 ` end